83023-58-9

Usage

Uses

Used in Medicinal Chemistry:
(2S)-5-BROMO-3-(2-PYRROLIDINYL)PYRIDINE is used as a chemical compound in medicinal chemistry for its potential pharmacological properties. Its unique structure, including the brominated pyridine and pyrrolidinyl group, may offer advantages in the development of new drugs.
Used in Drug Development:
In the field of drug development, (2S)-5-BROMO-3-(2-PYRROLIDINYL)PYRIDINE is utilized as a candidate molecule for the creation of novel therapeutic agents. Its specific properties and interactions with biological targets are under investigation to determine its suitability for various medical applications.
Note: Since the provided materials do not specify particular applications or industries for (2S)-5-BROMO-3-(2-PYRROLIDINYL)PYRIDINE, the uses listed are general and based on the potential of the compound in medicinal chemistry and drug development. Further research would be needed to identify specific applications and industries where (2S)-5-BROMO-3-(2-PYRROLIDINYL)PYRIDINE could be utilized.

InChI:InChI=1/C9H11BrN2/c10-8-4-7(5-11-6-8)9-2-1-3-12-9/h4-6,9,12H,1-3H2/t9-/m0/s1

Upstream product

• 71719-06-7 5-Bromo-3-(2-pyrrolidinyl)pyridine 
• 360767-36-8 (S)-3-(1-azidobut-3-enyl)-5-bromopyridine 
• 263888-14-8 (2'S)-N'-[(1R,2S,5R)-Menthoxycarbonyl]-5-bromonornicotine 
• 64319-85-3 3-bromo-5-(4,5-dihydro-3H-pyrrol-2-yl)-pyridine 
• 1005342-85-7 3-Bromo-5-{(S)-1-[(R)-1-(4-methoxy-phenyl)-ethyl]-pyrrolidin-2-yl}-pyridine 
• 20986-40-7 ethyl 5-bromo-3-pyridinecarboxylate 
• 360767-38-0 (R)-methanesulfonic acid 1-(5-bromopyridin-3-yl)but-3-enyl ester 
• 360767-40-4 (R)-1-(5-bromopyridin-3-yl)but-3-en-1-ol 
• 360767-46-0 1-(5-bromopyridin-3-yl)but-3-en-1-one 
• 360767-43-7 1-(5-bromopyridin-3-yl)but-3-en-1-ol 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 113118-81-3 5-bromopyridine-3-carbaldehyde 

Downstream Products

• 494-97-3 nornicotine 
• 179120-92-4 altinicline 
• 350820-86-9 (2S)-2-(3-pyridinyl)-1-pyrrolidinebutanoic acid phenylmethyl ester 
• 350820-75-6 N-[1-oxo-6-[(2S)-2-(3-pyridinyl)-1-pyrrolidinyl]hexyl]-β-alanine phenylmethyl ester 
• 1020176-96-8 ((S)-1-{(S)-2-[(S)-2-(5-Bromo-pyridin-3-yl)-pyrrolidin-1-yl]-1-cyclohexyl-2-oxo-ethylcarbamoyl}-ethyl)-methyl-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Pyrrolydine Derivatives as IAP Inhibitors

The present invention relates to novel IAP inhibitor compounds of: Formula (I).

Enantioselective reduction of heteroaromatic β,γ-unsaturated ketones as an alternative to allylboration of aldehydes. Application: Asymmetric synthesis of SIB-1508Y

Enantioselective reduction of heteroaromatic β,γ-unsaturated ketones was found to be an efficient and convenient alternative to the allylboration of corresponding aldehydes. This new method was used for the formal asymmetric synthesis of SIB-1508Y 2.

The first enantioselective synthesis of (S)-5-bromo-3-(1-methyl-2-pyrrolidinyl)pyridine: A key intermediate for the preparation of SIB-1508Y

The first enantioselective synthesis of (S)-5-bromo-3-(1-methyl-2-pyrrolidinyl)pyridine is described via intramolecular hydroboration-cycloalkylation of an azido-olefin intermediate. The chiral homoallylic alcohol was efficiently synthesized by enantioselective reduction of the corresponding ketone using (+)-diisopinocamphenylchloroborane as the key reaction. The total synthesis of (S)-SIB-1508Y was achieved with an enantiomeric excess (e.e.) of 94% in ten steps and in 18% overall yield from the commercially available 5-bromo-3-pyridinecarboxylic acid.

Metabolism of N'-nitrosonornicotine enantiomers by cultured rat esophagus and in vivo in rats

People who use tobacco products are exposed to considerable amounts of N'-nitrosonornicotine (NNN), a well-established esophageal carcinogen in rats. NNN is believed to play a significant role as a cause of esophageal and oral cavity cancer in smokers and